Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
about
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
@en
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
@nl
type
label
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
@en
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
@nl
prefLabel
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
@en
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
@nl
P2093
P2860
P50
P356
P1476
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
@en
P2093
Anne-Cécile Paepegaey
Carole Ratour
Gaëlle Lethielleux
Nora Kramkimel
P2860
P304
P356
10.1210/JS.2017-00170
P577
2017-04-28T00:00:00Z